Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MYC | P01106 | 2/20 | 0.52 |
| ▸ | MAX | P61244 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20610599 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPTHTTTDP1ATM | |
| SCHEMBL1341197 | 0.83 | L3MBTL1 (0.60) | ALDH1A1MAPTMYCMAXAR | |
| SCHEMBL310522 | 0.83 | MAPT (0.57) | ALDH1A1MAPTHTTTDP1ATM | |
| SCHEMBL12040956 | 0.82 | MYC (0.52) | MAPTMYCMAXARPELP1 | |
| SCHEMBL1341846 | 0.81 | RAB9A (0.66) | ALDH1A1MAPTHTTTDP1L3MBTL1 | |
| SCHEMBL12059549 | 0.81 | AR (0.53) | ALDH1A1MAPTMYCMAXAR | |
| SCHEMBL3514013 | 0.80 | MAPT (0.53) | ALDH1A1MAPTHTTTDP1ATM | |
| SCHEMBL2369186 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPTHTTTDP1ATM | |
| SCHEMBL1038678 | 0.80 | TDP1 (0.53) | ALDH1A1MAPTHTTTDP1ATM | |
| SCHEMBL12040911 | 0.79 | MYC (0.50) | ALDH1A1MAPTMYCMAXHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275299-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | NORTH CHINA PHARMACEUTICAL NEW DRUG R&D CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
| EP-3199536-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | North China Pharmaceutical New Drug R&D Co., Ltd. (DE) | 2017-08-02 | — | — | EP | disclosed |
| EP-2162454-B1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-2005177-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | Tibotec Pharmaceuticals Ltd. (IE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | ALDH1A1 3410/4885MAPT 2367/4885MYC 1980/4885 |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | C1QBP, CD4, CHRM4 | ALDH1A1 4806/4885MAPT 177/4885MYC 1234/4885 |
| US-20170275299-A1 | PREPARATION METHOD FOR BENZOXAZOLEOXAZINE KETONE COMPOUND AND INTERMEDIATE AND CRYSTAL FORM THEREOF | CYP4F11, CYP51A1, CYP2F1 | ALDH1A1 870/4885MAPT 1877/4885MYC 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.